Larson Financial Group
DSGN icon

Larson Financial Group’s Design Therapeutics DSGN Stock Holding History

Larson Financial Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.07K Buy
642
+461
+255% +$6.37K ﹤0.01% 2615
2026
Q2 		$2.62K Hold
181
– – ﹤0.01% 3036
2026
Q1 		$1.93K Buy
181
+178
+5,933% +$1.8K ﹤0.01% 2966
2025
Q4 		$28 Hold
3
– – ﹤0.01% 3405
2025
Q3 		$23 Buy
+3
New +$15 ﹤0.01% 3390

Other funds holding DSGN

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Larson Financial Group's DSGN Position: Q3 2026 in Review

Larson Financial Group increased its Design Therapeutics (DSGN) stake by 255% in Q3 2026, buying an estimated $6.37K and bringing the position to 642 shares worth $8.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Larson Financial Group first reported a position in DSGN in Q3 2025 and has held it in 5 quarters since. 68 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Larson Financial Group held 642 shares of Design Therapeutics worth $8.07K as of Q3 2026.
  • Larson Financial Group bought 461 Design Therapeutics shares in Q3 2026, an estimated $6.37K.
  • Design Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2615 holding.
  • Larson Financial Group first reported a position in Design Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 68 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.